Cargando…
Macular Atrophy Development and Subretinal Drusenoid Deposits in Anti-Vascular Endothelial Growth Factor Treated Age-Related Macular Degeneration
PURPOSE: To explore the association between presence of subretinal drusenoid deposits (SDD) at baseline in eyes with neovascular age-related macular degeneration (nAMD) with the development of macular atrophy (MA) during anti-vascular endothelial growth factor (VEGF) therapy. METHODS: There were 74...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Association for Research in Vision and Ophthalmology
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5710629/ https://www.ncbi.nlm.nih.gov/pubmed/29196768 http://dx.doi.org/10.1167/iovs.17-22378 |
_version_ | 1783282940234432512 |
---|---|
author | Zarubina, Anna V. Gal-Or, Orly Huisingh, Carrie E. Owsley, Cynthia Freund, K. Bailey |
author_facet | Zarubina, Anna V. Gal-Or, Orly Huisingh, Carrie E. Owsley, Cynthia Freund, K. Bailey |
author_sort | Zarubina, Anna V. |
collection | PubMed |
description | PURPOSE: To explore the association between presence of subretinal drusenoid deposits (SDD) at baseline in eyes with neovascular age-related macular degeneration (nAMD) with the development of macular atrophy (MA) during anti-vascular endothelial growth factor (VEGF) therapy. METHODS: There were 74 eyes without pre-existing MA receiving anti-VEGF therapy for nAMD for 2 years or longer analyzed. At least two image modalities that included spectral-domain optical coherence tomography, near-infrared reflectance, fluorescein angiography, and color fundus photos were used to assess for SDD presence, phenotype (dot and ribbon), and location, neovascularization type, and MA. Logistic regression models using generalized estimating equations assessed the association between SDD and the development of MA adjusting for age, neovascularization type, and choroidal thickness. RESULTS: SDD were present in 46 eyes (63%) at baseline. MA developed in 38 eyes (51%) during the mean of 4.7 ± 1.2 years of follow-up. Compared with eyes without SDD, those with SDD at baseline were 3.0 times (95% confidence interval [CI] 1.1–8.5, P = 0.0343) more likely to develop MA. Eyes with SDD present in the inferior macula and inferior extramacular fields at baseline were 3.0 times and 6.5 times more likely to develop MA at follow-up than eyes without SDD in these locations (95% CI 1.0–8.9, P = 0.0461 and 95% CI 1.3–32.4, P = 0.0218, respectively). MA development was not associated with a specific SDD phenotype. CONCLUSIONS: MA frequently developed in eyes during anti-VEGF treatment. SDD were independently associated with MA development. The extension of SDD into the inferior fundus, particularly in the inferior extramacular field, conferred higher odds of subsequent MA development. |
format | Online Article Text |
id | pubmed-5710629 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | The Association for Research in Vision and Ophthalmology |
record_format | MEDLINE/PubMed |
spelling | pubmed-57106292017-12-04 Macular Atrophy Development and Subretinal Drusenoid Deposits in Anti-Vascular Endothelial Growth Factor Treated Age-Related Macular Degeneration Zarubina, Anna V. Gal-Or, Orly Huisingh, Carrie E. Owsley, Cynthia Freund, K. Bailey Invest Ophthalmol Vis Sci Clinical and Epidemiologic Research PURPOSE: To explore the association between presence of subretinal drusenoid deposits (SDD) at baseline in eyes with neovascular age-related macular degeneration (nAMD) with the development of macular atrophy (MA) during anti-vascular endothelial growth factor (VEGF) therapy. METHODS: There were 74 eyes without pre-existing MA receiving anti-VEGF therapy for nAMD for 2 years or longer analyzed. At least two image modalities that included spectral-domain optical coherence tomography, near-infrared reflectance, fluorescein angiography, and color fundus photos were used to assess for SDD presence, phenotype (dot and ribbon), and location, neovascularization type, and MA. Logistic regression models using generalized estimating equations assessed the association between SDD and the development of MA adjusting for age, neovascularization type, and choroidal thickness. RESULTS: SDD were present in 46 eyes (63%) at baseline. MA developed in 38 eyes (51%) during the mean of 4.7 ± 1.2 years of follow-up. Compared with eyes without SDD, those with SDD at baseline were 3.0 times (95% confidence interval [CI] 1.1–8.5, P = 0.0343) more likely to develop MA. Eyes with SDD present in the inferior macula and inferior extramacular fields at baseline were 3.0 times and 6.5 times more likely to develop MA at follow-up than eyes without SDD in these locations (95% CI 1.0–8.9, P = 0.0461 and 95% CI 1.3–32.4, P = 0.0218, respectively). MA development was not associated with a specific SDD phenotype. CONCLUSIONS: MA frequently developed in eyes during anti-VEGF treatment. SDD were independently associated with MA development. The extension of SDD into the inferior fundus, particularly in the inferior extramacular field, conferred higher odds of subsequent MA development. The Association for Research in Vision and Ophthalmology 2017-12 /pmc/articles/PMC5710629/ /pubmed/29196768 http://dx.doi.org/10.1167/iovs.17-22378 Text en Copyright 2017 The Authors http://creativecommons.org/licenses/by-nc-nd/4.0/ This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. |
spellingShingle | Clinical and Epidemiologic Research Zarubina, Anna V. Gal-Or, Orly Huisingh, Carrie E. Owsley, Cynthia Freund, K. Bailey Macular Atrophy Development and Subretinal Drusenoid Deposits in Anti-Vascular Endothelial Growth Factor Treated Age-Related Macular Degeneration |
title | Macular Atrophy Development and Subretinal Drusenoid Deposits in Anti-Vascular Endothelial Growth Factor Treated Age-Related Macular Degeneration |
title_full | Macular Atrophy Development and Subretinal Drusenoid Deposits in Anti-Vascular Endothelial Growth Factor Treated Age-Related Macular Degeneration |
title_fullStr | Macular Atrophy Development and Subretinal Drusenoid Deposits in Anti-Vascular Endothelial Growth Factor Treated Age-Related Macular Degeneration |
title_full_unstemmed | Macular Atrophy Development and Subretinal Drusenoid Deposits in Anti-Vascular Endothelial Growth Factor Treated Age-Related Macular Degeneration |
title_short | Macular Atrophy Development and Subretinal Drusenoid Deposits in Anti-Vascular Endothelial Growth Factor Treated Age-Related Macular Degeneration |
title_sort | macular atrophy development and subretinal drusenoid deposits in anti-vascular endothelial growth factor treated age-related macular degeneration |
topic | Clinical and Epidemiologic Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5710629/ https://www.ncbi.nlm.nih.gov/pubmed/29196768 http://dx.doi.org/10.1167/iovs.17-22378 |
work_keys_str_mv | AT zarubinaannav macularatrophydevelopmentandsubretinaldrusenoiddepositsinantivascularendothelialgrowthfactortreatedagerelatedmaculardegeneration AT galororly macularatrophydevelopmentandsubretinaldrusenoiddepositsinantivascularendothelialgrowthfactortreatedagerelatedmaculardegeneration AT huisinghcarriee macularatrophydevelopmentandsubretinaldrusenoiddepositsinantivascularendothelialgrowthfactortreatedagerelatedmaculardegeneration AT owsleycynthia macularatrophydevelopmentandsubretinaldrusenoiddepositsinantivascularendothelialgrowthfactortreatedagerelatedmaculardegeneration AT freundkbailey macularatrophydevelopmentandsubretinaldrusenoiddepositsinantivascularendothelialgrowthfactortreatedagerelatedmaculardegeneration |